Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyjohns_hopkins_health_plans PAE Coverage Update | O…
    Ask Trek AI about this page
    Modifiedjohns_hopkins_health_plansPolicy CMS24.31

    Prostate Artery Embolization

    Customize your policy alerts

    Sign up for johns_hopkins_health_plans Policy CMS24.31 alerts

    Get alerted when Policy CMS24.31 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity criteria for prostate artery embolization (PAE) to treat benign prostatic hyperplasia (BPH) and related lower urinary tract symptoms for members of Johns Hopkins Health Plans lines of business.

    Policy Summary
    Payerjohns_hopkins_health_plans
    PolicyProstate Artery Embolization
    Policy CodePolicy CMS24.31
    Change TypeNew policy
    Effective Date07/01/2026
    Last ReviewApr 21, 2026
    Next Review Date
    Key ActionObtain prior authorization and document failure, contraindication, or refusal of prior medical therapy along with clinical notes (BPH diagnosis, IPSS, prostate sizing) before PAE is considered medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    New policy created for Prostate Artery Embolization.

    80-90%patients with meaningful IPSS improvement after PAE
    20-40%typical prostate volume reduction after PAE
    16-20%approximate re-intervention rate
    >80 cm³prostate size threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    07/01/2026effective date
    04/21/2026approval / MPAC decision date

    Coverage and Medical Necessity

    Medical necessity for Prostate Artery Embolization

    Covered when ALL of the following are met:

    A: When benefits are provided under the member's contract, PAE is medically necessary when ALL criteria in Section A.1 are met and ONE of the criteria in Section A.2 is met.

    From policy criteria

    A.1 Documentation Requirements: (a) Clinical notes confirming BPH diagnosis, International Prostate Symptom Score (IPSS), relevant urologic history, prostate gland sizing test results (e.g., ultrasound, MRI, CT) and rationale for PAE selection; (b) clinical notes stating prior medical therapy failed, was contraindicated, or refused by the member; (c) the procedure will be performed by an interventional radiologist or equivalent specialist with expertise in prostate artery embolization.

    Section IV.1

    A.2 Clinical Indications: One of the following: (a) Members with BPH and moderate to severe Lower Urinary Tract Symptoms (LUTS) AND at least one of: (i) large prostate glands (>80 cm³), (ii) member wishes to preserve erectile and/or ejaculatory function, (iii) member is not a surgical candidate due to advanced age, multiple comorbidities, coagulopathy, or inability to stop anticoagulation/antiplatelet therapy; OR (b) Members with BPH and acute or chronic urinary retention, in the setting of preserved bladder function as a method of achieving catheter independence; OR (c) Members with BPH and hematuria of prostatic origin as a method of achieving cessation of bleeding.

    Section IV.2

    Coverage when policy criteria met

    Policy covers PAE when MPAC-approved clinical criteria are met (see full policy for detailed criteria).

    General coverage condition: PAE is addressed as a treatment option for lower urinary tract symptoms due to BPH with supporting randomized and observational evidence cited; coverage requires meeting the policy's clinical review criteria.

    Detailed criteria are in the full policy body.

    PAE is considered not medically necessary for all other indications that are not explicitly listed in the policy's clinical criteria. This means that unless a member meets the specific documentation and clinical indication requirements described in the policy (e.g., BPH with moderate to severe LUTS plus one of the enumerated qualifying conditions), requests for PAE for other diagnoses or presentations will not meet medical necessity per this policy.

    The document fragment provided does not enumerate additional explicit exclusion conditions beyond the general noncoverage statement; however, the revision history indicates this is a new policy (approved 04/21/2026, effective 07/01/2026). Providers should consult the full policy text for any comprehensive exclusion language that may appear elsewhere in the complete policy document.

    Coverage for PAE is contingent upon the member meeting the policy's criteria and the member's contract providing benefits for the procedure. Per policy language, unless specific benefits are provided under the member's contract, PAE is not medically necessary for indications other than those listed in the clinical criteria.

    The current document excerpt does not contain detailed 'not medically necessary' statements beyond the general guidance; because this is a newly created policy, reviewers and providers should refer to the full policy body for the complete list of NMN determinations and any operational definitions that guide denial or coverage decisions.

    Billing and Code References

    Informational CPT CodesCPT
    37242Vascular embolization or occlusion; arterial, other than hemorrhage or tumor
    37243Vascular embolization or occlusion; for tumors, organ ischemia, or infarction
    Affected / Prior Authorization CPT/HCPCS codesmixed
    affected codesPolicy indicates affected codes for prior authorization and billing are specified in the policy.
    Prostate size threshold
    Prostate size threshold>80 cm³
    Context in clinical indicationsListed as ‘large prostate glands (>80 cm³)’ as one qualifying indication for PAE when LUTS are moderate to severe
    Measurement methods (documented)Prostate sizing test results (e.g., ultrasound, MRI, CT) required in clinical documentation per policy

    Provider Responsibilities and Authorization

    Prior Authorization

    Preauthorization required for inpatient admissions; informational CPT codes

    All inpatient admissions for PAE require preauthorization. The coding section lists CPT codes 37242 and 37243 for informational purposes only.

    • Note: Inclusion of CPT codes does not guarantee coverage or payment; verify member benefits.
    Prior Authorization

    Prior authorization required for PAE under new policy

    This is a new policy establishing coverage rules and prior authorization requirements for prostate artery embolization; affected billing codes for prior authorization are specified in the policy.

    • See policy CMS24.31 for the full list of affected prior authorization/billing codes.

    Clinical Background

    Prostate artery embolization (PAE) is a minimally invasive endovascular procedure performed by interventional radiology techniques that selectively embolizes prostatic arteries to reduce blood flow to the gland, causing ischemic shrinkage and symptomatic relief of lower urinary tract symptoms from benign prostatic hyperplasia. The policy release notes this is a new MPAC‑approved policy (approval 04/21/2026; effective 07/01/2026) establishing criteria and coverage rules for the procedure.

    Key Terms and Scores

    Benign Prostatic Hyperplasia (BPH) — definition and clinical features
    Definition (term)Benign Prostatic Hyperplasia (BPH)
    Core descriptionA nonmalignant adenomatous overgrowth of the periurethral prostate gland; a common, age-related, noncancerous enlargement that can cause bladder outlet obstruction
    Typical presenting symptomsWeak urinary stream, hesitancy, nocturia, urgency and other LUTS
    International Prostate Symptom Score (IPSS) — scoring categories
    Instrument nameInternational Prostate Symptom Score (IPSS)
    Mild category0-7
    Moderate category

    Policy Changes and Approval

    2026-04-21MPAC approval

    Policy reviewed and approved by the Medical Policy Advisory Committee (MPAC) on 04/21/2026 (signature on file).

    2026-04-21Policy created and approvedLatest

    New policy for Prostate Artery Embolization (Policy No. CMS24.31) was created and approved by MPAC on 04/21/2026, with an effective date of 07/01/2026.

    Policy Summary
    Payerjohns_hopkins_health_plans
    PolicyProstate Artery Embolization
    Policy CodePolicy CMS24.31
    Change TypeNew policy
    Effective Date07/01/2026
    Last ReviewApr 21, 2026
    Next Review Date
    Key ActionObtain prior authorization and document failure, contraindication, or refusal of prior medical therapy along with clinical notes (BPH diagnosis, IPSS, prostate sizing) before PAE is considered medically necessary.
    SourceLink
    On This Page
    Coverage and Medical NecessityBilling and Code ReferencesProvider Responsibilities and AuthorizationClinical BackgroundKey Terms and ScoresPolicy Changes and Approval
    Step Therapy

    Document prior medical therapy failure, contraindication, or refusal

    Documentation must show that prior medical therapy failed, was contraindicated, or was refused before PAE is considered medically necessary.

    • Clinical notes should explicitly state the nature and duration of prior medical therapy and the reason it was unsuccessful, contraindicated, or declined.
    Note

    Policy cites clinical guidelines and comparative trials

    The policy references guideline documents and randomized and observational trials that position PAE as a management option within the context of other treatments for BPH.

    • Examples cited include the SIR multisociety consensus statement and randomized trials such as PARTEM and other comparative studies.
    Documentation Required

    Required clinical documentation for prior authorization

    Prior authorization requests must include clinical notes confirming BPH diagnosis, IPSS, relevant urologic history, prostate sizing (e.g., ultrasound, MRI, CT), and the clinical rationale for selecting PAE.

    • Documentation must also state that the procedure will be performed by an interventional radiologist or equivalent specialist with PAE expertise.
    • Include objective prostate gland sizing test results and IPSS score values.
    Note

    Policy reviewed and approved by MPAC — follow MPAC criteria

    This policy was reviewed and approved by the Medical Policy Advisory Committee (MPAC); providers should follow MPAC-defined clinical review criteria in the policy.

    • MPAC approval date: 04/21/2026; Policy effective date: 07/01/2026.
    Denial Risk

    Risk of denial for lack of preauthorization

    Failure to obtain required preauthorization for inpatient admissions may result in denial or require additional review.

    • Adherence may be monitored and addressed through post-payment data analysis and medical review audits.
    Denial Risk

    Enforcement and denial risk under newly created policy

    New policy created and approved by MPAC; not meeting the newly specified policy criteria may result in denial per MPAC-approved policy.

    • Providers should ensure documentation meets all criteria specified in CMS24.31 to avoid coverage denial.
    8-19
    Severe category20-35
    Prostate Artery Embolization (PAE) — definition of procedure
    Procedure nameProstate Artery Embolization (PAE)
    Procedure typeA minimally invasive endovascular/interventional radiology procedure
    MechanismSelective embolization of the prostatic arteries to induce ischemic shrinkage of the prostate and relieve LUTS from BPH
    Prostate Artery Embolization (PAE) — alternative definition/description
    Alternative descriptionInterventional radiology procedure that embolizes prostatic arteries to reduce blood flow to the prostate, producing gland shrinkage and symptomatic improvement
    Clinical outcomes (literature referenced)Randomized and observational evidence, society consensus and HTA reports cited in references support PAE as a management option for LUTS due to BPH
    Guidance sourcesReferences include Society of Interventional Radiology multisociety consensus, Cochrane review, and contemporary clinical reviews